SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

NCT06210438 | Not Yet Recruiting Phase 2

• 1 other identifier: BCBM-003
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phaseⅡ, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases

Conditions

TNBC; Brain Metastasis

Outcome Measures

Primary Outcomes (1)

• CNS ORR

  The proportion of patients who have a CR or PR in the CNS, as determined by the Investigator according to RANO-BM criteria

  from enrollment to progression or death (for any reason), assessed up to 24 months

Secondary Outcomes (5)

• CNS CBR

  from enrollment to progression or death (for any reason), assessed up to 24 months

• Progression-free survival

  Up to 2 years

• Overall survival

  Up to 2 years

• First progression site

  Up to 2 years

• Safety as assessed by percentage of patients with any Adverse Event

  Up to 2 years

Study Arms (1)

SHR-A1921 + Bevacizumab

EXPERIMENTAL

Drug: SHR-A1921 + Bevacizumab

Interventions

SHR-A1921 + Bevacizumab DRUG

SHR-A1921 + Bevacizumab

SHR-A1921 + Bevacizumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years old, both genders
• ECOG Performance Status of 0-2
• Pathological tests confirm HR-negative/HER2-negative breast cancer；there is evidence of local recurrence or metastasis；not suitable with curative surgery or radiation therapy；HR negative is defined as: ER-negative and PR-negative, the proportion of positively stained tumor cells in all tumor cells is \<10%；HER2- negative is defined as: histologically confirmed to be HER2 IHC (0) or HER2 IHC(1+) or HER2 IHC (2+) and FISH(-)
• Must have life-expectancy of ≥ 3 months
• MRI confirmed brain metastases, at least one intracranial parenchymal metastatic lesion with a longest diameter ≥ 1.0 cm without prior radiotherapy；
• Intraventricular catheter shunting or mannitol、steroid hormone、anticonvulsant drug is allowed before enrollment, but the dose of drug should be stable for at least one week and the neurological symptoms are stable for ≥1 week
• Adequate function of major organs meets the following requirements (1)Blood routine
• ANC≥1.5×109/L；
• PLT≥75×109/L；
• Hb≥90 g/L(Allows blood transfusion or the use of medication to ensure that the content of hemoglobin) (2)Coagulation
• INR≤1.5，APTT≤1.5×ULN (3)Blood biochemistry
• TBIL≤1.5 × ULN;
• ALT and AST≤3 × ULN (liver metastasis≤5.0 × ULN);
• Urea nitrogen ≤ 1.5 × ULN; Cr≤1.5 × ULN or creatinine clearance ≥50 mL / min (Cockcroft-Gault formula) (4)Cardiac ultrasound
• LVEF≥50%; (5)12-lead ECG:

You may not qualify if:

• Leptomeningeal or cystic metastases confirmed by MRI or lumbar puncture
• Presence of third interstitial fluid that cannot be controlled by drainage or other methods (e.g., a large amount of pleural effusion and ascites);
• Whole brain radiotherapy, chemotherapy, biological targeted therapy, immunotherapy, surgery or endocrine therapy within 2 weeks prior to enrolment
• Has received prior therapy with bevacizumab and TROP-2 ADC drugs
• Participation in any other clinical trials within 2 weeks of enrollment
• Concurrent use of any other Anti-cancer drugs
• Other malignancies within 5 years, except cured in-situ of uterine cervix carcinoma , skin basal cell carcinoma and squamous-cell carcinoma
• History of heart disease: (1) Arrhythmias requiring medical treatment or clinical significance, (2) Myocardial infarction, (3) Heart failure, (4)Any heart diseases that investigator believes not suitable for this study
• History of allergy or hypersensitivity to any of the study drugs or study drug components
• History of immunodeficiency including HIV-positive, active hepatitis B/C, other acquired, congenital immunodeficiency disease or history of organ transplantation
• A clear history of neurological or mental disorders, including epilepsy or dementia
• Pregnant or breastfeeding women. Women of childbearing potential who have a positive pregnancy test or unwilling to use adequate contraception prior to enrollment and for the duration of study participation
• According to the investigator\'s judgment, there is a concomitant disease that seriously endangers the safety of subjects or affects the completion of the study (including but not limited to severe hypertension, severe diabetes, active infection, thyroid disease that cannot be controlled by drugs)
• Any condition which in the investigator\'s opinion makes the subjects unsuitable for the study participation

Sponsors & Collaborators

• Fudan University: lead

Study Sites (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

Location

MeSH Terms

Conditions

Brain Neoplasms

Interventions

Bevacizumab

Condition Hierarchy (Ancestors)

Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Biyun wang

  Fudan University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Biyun Wang

CONTACT

18017312387; pro_wangbiyun@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 4, 2024
• First Posted: January 18, 2024
• Study Start: February 1, 2024
• Primary Completion: June 30, 2025
• Study Completion (Estimated): June 30, 2026
• Last Updated: January 18, 2024

Record last verified: 2023-12

Locations

CN (1)